Milk contains biologically relevant concentrations of erythropoietin (Epo), the primary hormone responsible for erythrocyte production. In animals, milk-borne Epo stimulates erythropoiesis. Epo receptors have been found in nonerythropoietic tissues including gastrointestinal tract. We hypothesized that milk-borne Epo is distributed to local gastrointestinal tissues, absorbed intact, and then distributed peripherally via the systemic circulation. Rat milk protected recombinant human Epo (rhEpo) from degradation in the suckling rat gastrointestinal tract. Simulated digestion of 125 I-rhEpo in suckling rat gastrointestinal juices was performed. When measured by acid precipitation and immunoassay, rat milk protected rhEpo from gastrointestinal juices better than saline (p Ͻ 0.0001). The fate of enterally administered milk-borne 125 I-rhEpo was examined in 10-d-old rats. RhEpo fed in rat milk was better protected from in vivo proteolytic degradation than rhEpo in saline (p Ͻ 0.05). After enteral 125 I-rhEpo dosing, radiolabeled protein from gastric tissue comigrated on SDS-PAGE with intact rhEpo at 36.5 kD. To determine the local and systemic distribution of physiologic intakes of rhEpo, suckling rats were fed 125 I-rhEpo in rat milk, and tissues were harvested 1, 2, and 4 h later. Intact 125 I-rhEpo was found in gastric and small intestinal walls and lumens. Five percent of total administered dose was found intact in the plasma, whereas another 8 to 10% of total administered dose was localized to bone marrow, percentages comparable to those seen after parenteral administration. Radiolabel was also localized to liver and peripheral solid tissues. These patterns of localization and degradation of rhEpo after acute administration support both systemic absorption and gastrointestinal cellular processing. Epo, the primary hormone regulating erythropoiesis, is produced in response to hypoxia or anemia. In addition to its erythropoietic effects, Epo binds to its receptor (EpoR) and exerts mitogenic, vasodilatory, and angiogenic effects in a diverse group of nonerythropoietic tissues including gastrointestinal tract (1) (2) (3) (4) . Like many other cytokines and hematopoietic growth factors, biologically relevant levels of Epo are present in human milk (5) .
In the neonate, immature gastrointestinal proteolysis, combined with the intrinsic proteolytic inhibition of milk and greater intestinal mucosal permeability, allows undigested milk-borne proteins to be absorbed and delivered to distant sites via blood (6 -8) . In vitro digestion studies with human neonatal gastric juices have shown that Epo in saline is partially degraded, but the presence of human milk inhibits proteolytic degradation of Epo (5) .
Previously published work has evaluated erythropoiesis after enteral Epo administration. In adult rats, enterally administered rhEpo exhibits no erythropoietic effects except when given rectally in the presence of salicylates that improve rectal mucosal permeability (9) . Erythropoiesis was stimulated in suckling rats after maternal hypoxia or anemia or after enteral supplementation of cow's milk with Epo (10 -12) . In human premature infants, two preliminary studies support that enteral rhEpo is absorbed (13, 14) . Both Britton et al. (13) and Ballin et al. (14) showed higher plasma Epo levels after enteral rhEpo administration, and Ballin, et al. observed reticulocytosis and lower plasma ferritin levels with enteral rhEpo treatment (14) .
To date, no studies have examined the nonerythropoietic effects of enterally administered rhEpo despite several lines of investigation indicating that Epo plays a role in gastrointestinal biology. For example, in vitro studies suggested that rhEpo caused proliferation of gastric and intestinal mucosa after receptor binding (3, 4) . Recently, a clinical study has shown that parenteral rhEpo therapy is associated with a lower incidence of necrotizing enterocolitis (15) . To begin to address the potential nonerythropoietic roles of enteral rhEpo, we first needed to assess the level of absorption and distribution of enterally administered rhEpo. We selected the rat model because of its utility in investigating neonatal erythropoiesis (11, 16) and gastrointestinal tract development (17) and because rhEpo has been shown to have biologic activity in rats (18) . We set out to test the hypothesis that milk-borne Epo is distributed throughout the gastrointestinal tract, absorbed into systemic circulation, and delivered to hematopoietic tissues.
METHODS

Experimental Design
Animals. The present study was approved by the Institutional Animal Care and Use Committee. Sprague-Dawley rats were bred and delivered in-house, with litters reduced to 10 pups on the second postnatal day to standardize litter size. Rat milk was manually expressed from dams after 10 g/kg fentanyl anesthesia and 2 U oxytocin after removal of her litter for 5 h (19) and was stored at Ϫ70°C until use. RMS formula was prepared (20) and studied fresh within 4 d. On the day of study, suckling rats were weighed after removal from their mothers, sex was determined by examination, and they were fasted on a 33°C heating pad to maintain normal body temperature. Before sampling and death, the rats were given inhaled ether or a ketamine and xylazine mixture (1:1) s.c.
In vitro digestion assay. For collection of gastric and proximal small intestinal juices, 10-d-old rats were fasted for 2 h, fed Pedialyte via gastric tube, and fasted for an additional 2 h before anesthesia and death. Gastric and proximal small intestinal luminal contents were harvested by flushing with 1 mL of saline and stored at Ϫ70°C. To approximate neonatal gastrointestinal physiology, three incubation buffers were used: 1) 0.1 M glycine, pH 3.2, to simulate preprandial gastric conditions; 2) 0.1 M maleate, pH 5.8, to simulate postprandial gastric conditions; and 3) 0.01 M Tris, 6.7 mM CaCl 2 , pH 7.4, to simulate proximal small intestine (5, 21) .
Equivalent volumes of buffer, aqueous fraction of neonatal gastric juice, and substrate were incubated at 37°C for 15 min (baseline degradation) and 2 h to span the normal stomach and small intestine transit time (5, 22) . Substrates included 1) saline, 2) RMS artificial formula, and 3) aqueous fraction of rat milk. Substrates were supplemented with 10,000 cpm 125 IrhEpo (Amersham) in 150 mU/mL rhEpo (Amgen) to evaluate degradation via TCA precipitation (5) or 150 mU/mL of unlabeled rhEpo to evaluate degradation via RIA (Diagnostic Systems Laboratories, Inc., Webster, TX, U.S.A.). We selected 125 I-rhEpo with lower specific activity (300 -900 Ci/mM) as previous studies showed it displayed greater biologic stability and normal receptor binding (23) . Gastric juice samples (n ϭ 5) were incubated at pre-and postprandial pH with all three substrates, and proximal small intestinal juices (n ϭ 5) were incubated at pH 7.4 with all three substrates. Reactions were stopped with addition of 1 M Tris, pH 8. Radioactivity for both TCA and RIA assays was detected with a Cobra AutoGamma Counter (Packard Instruments, Meriden, CT, U.S.A.). TCA was used to precipitate large proteins, leaving digested products in the supernatant. BSA was used as a carrier protein to ensure good separation of the TCA pellet (5, 24) . Cold TCA in BSA was added to the reaction mixtures to a final concentration of 12% TCA, 2% BSA. Reaction mixtures were centrifuged at 16,000 ϫ g for 20 min at 4°C, supernatants were decanted from pellets, and both were counted separately to determine percent intact radiolabeled proteins. Enteral 125 I-rhEpo studies. Suckling rats were fasted for 5 h, then fed 75,000 -100,000 cpm 125 I-rhEpo in 400 mU rhEpo delivered in 200 L of rat milk. The rat milk aliquots had assayable Epo, but the added rhEpo dose was 50 -100 times endogenous levels, which should not alter rhEpo disposition patterns. The rhEpo dosing was not pharmacologic; rather, it was twice the estimated physiologic daily intake to evaluate normal physiologic distribution. To ensure stability and equal distribution, mixtures were kept at 4°C, then vortexed and warmed before administration. Feeds were bolused via an orogastric tube (3.5F umbilical catheter, Sherwood Medical) advanced to 5 cm. Death occurred immediately (0 h), 1, 2, or 4 h after 125 I-rhEpo administration. The immediate (0 h) sampling time represented dosing baseline, 1-h sampling represented maximal gastric proteolytic activity (25), 2-h sampling represented stomach emptying (22) , and 4-h sampling was chosen to evaluate rhEpo distribution after gastric emptying. Each time interval included at least 10 animals obtained from three litters. A comparison group of parenterally (s.c.) dosed rats was studied 2 h after injection with 75,000 -100,000 cpm 125 I-rhEpo in 400 mU of rhEpo mixed in 200 L of 2.5% BSA in saline in the dorsal neck area.
Tissue collection. After anesthesia, cardiac puncture was performed, whole blood microhematocrit was determined, and remaining blood was placed into Becton Dickinson EDTA Microtainers (Franklin Lakes, NJ, U.S.A.). After counting, whole blood tubes were centrifuged at 1000 ϫ g for 1 min, and plasma was removed. After cardiac puncture, the animals were decapitated and tissues harvested as described by Philipps et al. (7) . Briefly, the stomach, small intestine, and colon were removed, and the small intestine was divided into duodenum, jejunum, midjejunum, and ileum (7). The gastrointestinal segments were flushed with 2 mL of ice-cold 1 M Tris buffer, pH 8.0, containing protease inhibitors (26) . The liver, spleen, brain, and kidneys were removed. Each tissue/luminal flush was placed in preweighed 12 ϫ 75 polypropylene tubes and weighed and frozen at Ϫ70°C. All specimens collected underwent TCA precipitation as described above. Before TCA precipitation, tissue and luminal flushes were homogenized for 30 s each by use of a Polytron homogenizer (Brinkman Instruments, Westbury, NY, U.S.A.). TCA and BSA were added to the tissues and flushes as described above.
SDS-PAGE. Molecular size of label from gastric tissue and luminal contents was determined by SDS-PAGE. The protein 262 fraction of tissue and lumen homogenates was extracted following the manufacturer's instructions for Tri-Pure isolation reagent (Boehringer Mannheim, Indianapolis, IN, U.S.A.). A 4% polyacrylamide stacking and 15% polyacrylamide running gel was poured into a Bio-Rad Mini Protean II gel apparatus (Bio-Rad, Hercules, CA, U.S.A.). Samples containing 500 -1000 cpm were loaded into each well and run for 1 h at 140 V along with prestained standards. Gels were placed into plastic sleeves, exposed on X-omat AR film (Kodak, Rochester, NY, U.S.A.) at Ϫ70°C for 2 wk, and developed. The x-ray film was scanned and imaged with a Umax Vista-S6 scanner (Fremont, CA, U.S.A.) and Adobe Photoshop (Mountain View, CA, U.S.A.).
Bone harvest. The distribution of 125 I-rhEpo cpm in bone at 1, 2, and 4 h after enteral feeding and 2 h after parenteral administration was determined. Bones were stripped of soft tissues, separated at joints, weighed, and placed in the gamma counter. Total counts of each bone group were compared with its weight. Because TCA precipitation could not be performed on the whole bone specimens, marrow biopsies from long bones were harvested from an additional group of rats at 1, 2, and 4 h after enteral feeding and 2 h after parenteral administration for TCA determination of intact and total 125 I-rhEpo counts.
Data analysis. Simulated digestion TCA precipitation data and intact Epo levels are expressed as percent of the total 125 I-rhEpo Ϯ SEM. RIA Epo levels and controls were calculated with polynomial regression (Statview 4.01) according to manufacturer's instructions. Enteral rhEpo studies are expressed as percent of the dose administered in total and acidprecipitable cpm Ϯ SEM. In enteral rhEpo studies, the dose administered was calculated by administering separate aliquots of the 200-L feeding volume into tubes and counting and then was confirmed by tallying all tissue cpm from the baseline (0 h) samples. The total counts of a blood aliquot were used to calculate the counts of the total blood volume, assuming that blood comprises 7% of body weight. Data were analyzed by 2-tailed paired or unpaired t tests or 1-way ANOVA for multiple comparisons with Fisher's post hoc testing. An alpha level Ͻ 0.05 was considered significant.
RESULTS
We evaluated the capacity of rat milk and artificial RMS to protect rhEpo from proteolytic degradation after in vitro exposure to suckling rat gastric juices at pH 3.2 and 5.8 and intestinal juices at pH 7.4 (Fig. 1, A and B) . By use of TCA precipitation to estimate intact rhEpo, at 2 h of incubation in gastric juices at pre-and postprandial stomach pH, we found that 125 I-rhEpo levels were higher in milk or RMS than in saline (F 2,12 ϭ 122.6, p Ͻ 0.0001, F 2,12 ϭ 14.3, p Ͻ 0.001, respectively, with post hoc p Ͻ 0.05). Similarly, 125 I-rhEpo levels in small intestinal juices were higher in milk or RMS than in saline (F 2,12 ϭ 14.6, p Ͻ 0.001, with post hoc p Ͻ 0.05). In small intestinal juices, 125 I-rhEpo levels in milk were higher than RMS (with post hoc p Ͻ 0.05). With RIA, we measured rhEpo after simulated digestion for 2 h and found that after 2 h, immunoreactive rhEpo levels were higher in milk or RMS than in saline alone when incubated in gastric (preand postprandial pH levels) and small intestinal juices (F 2,12 ϭ 54.0, p Ͻ 0.0001, F 2,12 ϭ 18.8, p Ͻ 0.001, F 2,12 ϭ 13.9, p Ͻ 0.001, respectively, with post hoc p Ͻ 0.05). In small intestinal juices, rhEpo levels in rat milk were higher than in RMS (with post hoc p Ͻ 0.05). TCA analysis overestimated measured immunoreactive Epo; however, degradation patterns seen with TCA analysis and RIA were similar.
The ability of rat milk to protect rhEpo from gastrointestinal proteolytic degradation was also evaluated in vivo at 1, 2, and 4 h after feeding. Except where noted, data shown represent the findings of the 2-h postfeed point because peripheral distribution of 125 I-rhEpo was observed to peak in most tissues at this time. We found that 125 I-rhEpo from stomach wall and lumen migrated at the same molecular weight as unfed intact 125 IrhEpo, 36.5 kD, on a 15% SDS-PAGE gel (Fig. 2) . Because the TCA method approximates intact Epo both in vitro and in vivo, we used it to show that enteral 125 I-rhEpo is better protected from gastrointestinal proteolytic degradation when adminis- On the horizontal axis, the substrates are grouped into three digestion groups: gastric juices at preprandial pH (3.2) and postprandial pH (5.8) and intestinal juices at pH 7.4. The substrates used are rat milk (RM) (white bars), RMS (gray bars), and saline (S) (black bars). Both TCA and RIA assays measured higher rhEpo levels in RM or RMS than in S (post hoc testing), *p Ͻ 0.05. In both assays, rhEpo levels were higher in RM than RMS in the intestinal juices (post hoc testing), †p Ͻ 0.05.
ABSORPTION OF ENTERAL ERYTHROPOIETIN
tered in rat milk versus saline in 0.25% BSA (gastric, jejunal and ileal lumens, and jejunal and ileal walls, p Ͻ 0.05) (Fig. 3) .
Intact rhEpo is distributed locally to gastrointestinal tissues and peripherally to distant tissues. Distribution of total and acid-precipitable counts as percent total 125 I-rhEpo dose administered in the gastrointestinal tissues, corresponding lumens, and distant sites 2 h after enteral administration is shown in Figure 4 . Because gastrointestinal lumen contains digestive juices and gastrointestinal wall possesses EpoR, we transformed the data from stomach, duodenum, jejunum, and midjejunum in Figure 4 to show the ratio of acid-precipitable (intact) counts over total counts (Fig. 5 ) in lumen and wall. In stomach, duodenum, and midjejunum, relatively more Epo located in the wall has undergone degradation compared with Epo located in corresponding lumen.
Epo as an endocrine hormone is delivered to the bone marrow via the circulation. Figure 6 shows that at 1, 2, and 4 h after enteral administration, 5% of the total 125 I-rhEpo dose is found intact in the plasma fraction of blood. This percentage is comparable to percentages of s.c. dosed rhEpo seen in plasma by ourselves and others (27, 28) . Eight, 9, and 10% of the total enterally administered dose reached bone marrow at 1, 2, and 4 h, respectively (Fig. 6) . Representative marrow biopsies showed that 2.7% of total administered dose was intact in bone marrow between 1-4 h after feeding (data not shown). During infancy, all bone marrow is hematopoietic (29), so we compared bone marrow distribution of counts after enteral and parenteral (s.c.) administration. At 2 h, the percentage of administered total counts reaching the bone marrow is similar whether dosed enterally (9%) or parenterally (8%). In a subset of rats dosed enterally (n ϭ 2) or parenterally s.c. in the posterior neck near the foreleg (n ϭ 2) and killed at 2 h after dose, bones were dislocated at predetermined joints, counted, and counts were correlated with bone weight (Fig. 7) . This correlation was stronger after enteral administration (R 2 ϭ 0.80, p Ͻ 0.0001) than after s.c. administration (R 2 ϭ 0.493, p Ͻ 0.02), supporting a more even distribution of rhEpo to hematopoietic tissues after enteral administration.
DISCUSSION
Similar to our previous work with human milk (5), the presence of rat milk or RMS formula protects rhEpo from degradation by rat gastric and small intestinal juices in the in vitro digestion assay as measured by TCA precipitation or RIA. When comparing the in vitro studies of rhEpo in rat milk, relative amounts of intact rhEpo measured by TCA precipitation and RIA are remarkably similar (85 to 98% of initial dose found as intact). However, the TCA and RIA methods were more discrepant in comparing rhEpo in RMS or saline. Percentage of intact rhEpo when in RMS appears higher with TCA (65 to 85%) compared with RIA (25 to 65%). Additionally, when rhEpo was in saline, the TCA method showed a much higher percentage of intact rhEpo (35 to 75%) compared with RIA (5 to 25%). TCA studies may overestimate intact proteins such as Epo. Widness et al. (27) found that TCA precipitation overestimates rhEpo by 10 to 30% after parenteral rhEpo administration when compared with immunoprecipitation, immunoassay, or bioassay techniques, presumably as TCA precipitates the larger degradative products of rhEpo. An additional explanation of the findings in RMS and saline is that these vehicles lack specific protease inhibitors contained in rat milk (8) and gastrointestinal juices degraded rhEpo samples during the 24 h at room temperature while the RIA was being performed compared with the TCA precipitation method that took only minutes to perform.
We selected acid precipitation as a first step in these in vitro and in the in vivo degradation studies, secondary to its ease of use in localizing and determining the fate of other enteral growth factors in previous studies (7, 30, 31) . Our initial disposition studies show that when rhEpo is present in rat milk, TCA results correlated very highly with RIA, and in vivo studies identify intact rhEpo in local gastrointestinal tissues, systemic circulation, and distant tissues. However, the abovereported TCA method is of insufficient specificity for precise pharmacokinetic plasma studies (27) , and additional studies with a more specific method such as immunoprecipitation are necessary to analyze whether escalating pharmacologic doses result in higher levels in plasma and bone marrow.
Proteins such as rhEpo are spared from gastrointestinal degradation because the neonatal gastrointestinal tract exhibits relatively less proteolytic activity and more mucosal permeability to intact proteins than later in life (6, 8) . Milk itself further protects proteins from degradation by raising gastric pH, which limits conversion of proteolytic enzymes to their active forms and by providing specific inhibitors of proteolytic enzymes (8) . It is likely that cow's milk-based artificial formulas are less effective in protecting proteins from degradation. A previous study in suckling rats suggested that erythropoietic effects of enteral rhEpo administration are greatest in the presence of milk (11) . Two human studies observed that plasma Epo levels in premature infants rose after enteral rhEpo administration (13, 14) , but measurable changes in erythropoiesis occurred only after rhEpo was administered in infant formula (14) . We have confirmed these findings with our suckling rat studies. We have shown with this work that enterally administered rhEpo resists proteolytic degradation, especially in the presence of rat milk, and that milk-borne rhEpo is distributed throughout the gut, to hematopoietic tissues, and to other peripheral organs.
Previous published studies of enteral Epo in suckling animals (10 -12, 32) and premature human infants (13, 14) report only the erythropoietic effects of Epo. However, EpoR have been identified in gastrointestinal cells, and in vitro studies support physiologic roles of rhEpo in these cells (3, 4) . Before birth, the fetus swallows amniotic fluid rich in trophic and protective growth factors needed for gastrointestinal development (8, 33, 34) . Epo, one of these growth factors, is present at high levels in amniotic fluid and at higher levels during fetal hypoxia (35, 36) . We found biologically relevant amounts of intact rhEpo distributed to the local gastrointestinal tract, the plasma, and peripheral organs after enteral rhEpo administration. Relatively greater degradation is observed within the wall of the stomach and small intestine compared with the lumen. As wall possesses EpoR, these data support a potential role for tissue receptor-mediated endocytosis rather than luminal proteolytic degradation. Epo is degraded rapidly by lysosomes after ligand-occupied EpoR are internalized by endocytosis (23, 37, 38) . With physiologic doses of rhEpo such as ours, this pathway of degradation is rapid but slows as doses increase and receptors are saturated (37, 39) . This phenomenon needs further study with higher enteral doses of rhEpo and more specific assay methods.
At 1, 2, and 4 h after feeding, plasma Epo levels remained steady at 5% of the total dose given, which suggests a steady supply of intact rhEpo. Subcutaneously administered rhEpo in humans results in a similar pattern with relatively low steady plasma levels (40, 41) and is generally considered to be more efficacious than i.v. bolus (42) . Continuous i.v. infusion also results in steadier plasma concentrations and appears to be more efficacious than i.v. bolus (43) . The finding that 5 and 2.7% of our administered dose was intact in plasma and bone marrow, respectively, is similar to the percentages seen in rats administered i.v. bolus Epo (28) . It is important to note, however, that the plasma Epo levels we report here remained steady at 5% of the dose for at least 4 h, unlike the rapid peak and fall seen with i.v.-administered Epo (44, 45) . The percentage of total dose reaching bone marrow was similar whether dosed enterally or s.c., but enteral dosing resulted in a more even distribution per gram of bone. As nearly all marrow is hematopoietic in neonates (29) and EpoR in marrow may saturate with relatively low (1.25 U/kg) rhEpo i.v. bolus doses (43) , the low-level steady delivery of rhEpo enteral administration may offer an advantage over i.v. bolus in the clinical setting.
In summary, we observed that milk protects rhEpo from proteolytic degradation and that enterally administered radiolabeled rhEpo is distributed locally in the gastrointestinal tract and peripherally to the plasma, bone marrow, and other distal organs. Our current results are the first in vivo data to show that rhEpo is distributed in a pattern suggesting both local gastrointestinal cellular processing and systemic absorption. These findings warrant continued investigation into the fate, pharmacokinetics, tissue receptor binding, and biologic roles of enterally administered rhEpo.
